By Josh White
Date: Thursday 29 Jan 2026
(Sharecast News) - Sanofi reported strong fourth-quarter and full-year results for 2025 on Thursday, underpinned by robust growth from its blockbuster asthma and dermatology treatment Dupixent, while forecasting another year of profitable growth in 2026 despite lingering concerns over its pipeline and vaccine demand.
No recent information was found.
| Currency | Euro |
| Share Price | 79.20 |
| Change Today | 2.12 |
| % Change | 2.75 % |
| 52 Week High | 109.62 |
| 52 Week Low | 76.86 |
| Volume | 3,186,159 |
| Shares Issued | 1,256.00m |
| Market Cap | 99,475m |
| Beta | 0.81 |
| Strong Buy | 13 |
| Buy | 7 |
| Neutral | 6 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 27 |

| Time | Volume / Share Price |
| 17:39 | 63 @ 79.20 |
| 17:38 | 400 @ 79.20 |
| 17:38 | 1 @ 79.20 |
| 17:37 | 94 @ 79.20 |
| 17:37 | 150 @ 79.20 |
You are here: research